Chronic obstructive pulmonary disease (COPD)
Conditions
Interventions
After 4 weeks of administration of tiotropium, both oral theophylline(200-800mg/day) and tiotropium will be administerd for 4 weeks.
Sponsors
Graduate school of biomedical sciences, Hiroshima university, department of molecular and internal medicine
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: COPD patient with a persistant symptoms(chronic cough, sputum, dyspnea), 45 years old or older, Post bronchodilator FEV1/FVC<70%, Smoking history 10 pack-years or more Patients who have signed the agreement for participation in this study
Exclusion criteria
Exclusion criteria: Patients for whom theophylline or tiotropium is contraindicated Patients who have used other long acting bronchodilator, other xanthine, and inhaled corticosteroid within 1 month Patients with asthma Patients who need persistant oxygen therapy Patients with respiratory infection within 1 month Patients with severe hepatic, renal, heart, hematologic abnormality Patients with active tuberculosis or pulmonary sequelae of tuberculosis Patients with cancer within 2 years. (excluding basal cell carcinoma) Patients with cystic fibrosis and bronchiectasis Patients who are or could be pregnant In addition to the above exclusion criteria, patients judged to be inadequate to participate in this study by their physician
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Lung function test QOL (St George Respiratory Questionnaire) | — |
Secondary
| Measure | Time frame |
|---|---|
| Blood concentration of theophylline Induced sputum | — |
Countries
Japan
Contacts
Public ContactYoshinori Haruta
Graduate school of biomedical sciences, Hiroshima university Department of molecular and internal medicine
Outcome results
None listed